Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients with ventricular tachycardia indicated for an implantable cardioverter ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Ultra ...

Baltimore, MD - A report published this week has shown a high rate of ventricular tachycardia (VT) recurrence—as high as 75% at 14 months—in arrhythmogenic right ventricular dysplasia/cardiomyopathy ...

Please provide your email address to receive an email when new articles are posted on . Catheter ablation improved outcomes vs. antiarrhythmic drugs in patients with VT and ischemic cardiomyopathy.

May 6, 2011 (San Francisco, California) — Ablation of ventricular tachycardia (VT) in patients with verylow ejection fractions (EFs) results in high rates of early recurrence compared with individuals ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...

BERLIN, Germany—Performing ventricular tachycardia (VT) ablation before placement of a primary prevention implantable cardioverter-defibrillator (ICD) had a clinical benefit in a selected group of ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S.

Loyola Medicine is among two centers in the world offering a novel catheter ablation system intended to improve treatment outcomes for a life-threatening heart rhythm disorder called ventricular ...

Patients with structural heart disease and monomorphic ventricular tachycardia (VT), irrespective of its etiology, can benefit when early first-line catheter ablation is added before implanting an ...

Patients with structural heart disease are at risk for life-threatening ventricular tachycardias (VTs). Implantable cardioverter-defibrillators (ICDs) can terminate VT, but often at the cost of ...